Black Diamond Therapeutics (BDTX)
(Delayed Data from NSDQ)
$4.78 USD
+0.05 (1.06%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $4.77 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BDTX 4.78 +0.05(1.06%)
Will BDTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDTX
All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy
Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings?
BDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable
Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect?
Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for BDTX
Buy Rating Affirmed for Black Diamond Therapeutics Amid Promising NSCLC Treatment Advances
Piper Sandler Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)
Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
Buy Rating Reaffirmed for Black Diamond Therapeutics Amid Promising Clinical Trials and Solid Financials
Small-cap and mid-cap Health Care has room to rally - Roth MKM